Show simple item record

dc.contributor.authorZagolin B., Mónicaes
dc.contributor.authorWainstein G., Eduardoes
dc.contributor.authorUriarte G., Polentzi
dc.date.accessioned2013-10-22T18:50:54Z
dc.date.accessioned2016-05-31T15:38:41Z
dc.date.available2013-10-22T18:50:54Z
dc.date.available2016-05-31T15:38:41Z
dc.date.issued2006
dc.identifier.citationRevista Médica de Chile, Vol. 134, N° 7, pp. 902-909, 2006.
dc.identifier.issnISSN: 0034-9887
dc.identifier.otherDOI: 10.4067/S0034-98872006000700015
dc.identifier.urihttp://repositorio.unab.cl/xmlui/handle/ria/2042
dc.descriptionIndexación: Scielo
dc.description.abstractResumen: Pulmonary Arterial Hypertension includes a heterogeneous group of disorders with a common genetic, pathological and hemodinamyc origin. It is characterized by a high pulmonary artery pressure due to a primary vascular disease, as a consequence of genetic and environmental factors. The common pathway is a vascular imbalance towards vasoconstriction and proliferation inside the small vessels. According to the World Health Organization, 2003, Pulmonary Arterial Hypertension is classified as idiopathic, familiar or associated to connective tissue diseases, HIV, drugs, porto-pulmonary hypertension, congenital intracardiac shunts and others. The diagnosis is based in hemodynamics. Echocardiogram is a non invasive and right ventricular catheterization is an invasive diagnostic tool. Follow up is based on a clinical and functional assessment through functional class classification, dyspnea scores and 6-minute walking test. The prognosis is historically devastating but new therapies are changing the natural history of the disease. New treatments have demonstrated improvement in symptoms, hemodynamic profiles and survival. Intravenous, subcutaneous or inhaled prostanoids such as Epoprostenol, Treprostinil or Iloprost respectively have been approved for Pulmonary Arterial Hypertension treatment as well as oral endothelial receptor blockers. They are all considered first line treatments for arterial pulmonary hypertensive patients with even better benefits than lung transplantation. Phosphodiesterase inhibitors (Sildenafil), have been recently approved for the treatment of pulmonary arterial hypertension.
dc.description.urihttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872006000700015&nrm=iso
dc.languagespa
dc.publisherSociedad Médica de Santiago
dc.subjectHypertension
dc.subjectPulmonary
dc.subjectProstaglandins
dc.subjectReceptors
dc.subjectVascular endothelial growth factor
dc.subjectSildenafil
dc.subjectHipertension pulmonar
dc.titleActualización en el diagnóstico y terapéutica en hipertensión pulmonar arterial
dc.typeArtículo de revista


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record